These findings suggest that CPNE5 can be used as a biomarker for predicting ESCC recurrence, especially in patients with local recurrence, and can help ensure that patients receive optimal treatment and follow-up (Umeda et al., 2018). The gene discussed is CPNE5; the disease is esophageal squamous cell carcinoma.